| Gilead Sciences Splashes Out $300M for Tizona Stake & Option to Acquire | Sarah de Crescenzo | 07/21/20 | San Francisco |
| Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline | Frank Vinluan | 06/04/20 | Boston |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases | Sarah de Crescenzo | 03/26/20 | San Francisco |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors | Sarah de Crescenzo | 02/06/20 | San Francisco |
| BioIntervene Raises $30M to Move Nerve Pain Drug Into the Clinic | Sarah de Crescenzo | 01/07/20 | San Diego |
| Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s | Frank Vinluan | 12/17/19 | Boston |
| The Winners of the 2019 Xconomy Awards Boston Are… | Jeff Bauter Engel | 09/12/19 | Boston |
| Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes | Frank Vinluan | 09/03/19 | Boston |
| Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing | Frank Vinluan | 08/21/19 | Boston |
| The Finalists for the 2019 Xconomy Awards Are … | Angela Shah | 07/10/19 | Boston |
| ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups | Frank Vinluan | 05/13/19 | Boston |
| Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease | Frank Vinluan | 04/03/19 | Boston |
| Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials | Brian Dowling | 03/13/19 | Boston |
| Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More | Frank Vinluan | 02/22/19 | National |
| Entrada Therapeutics Nabs $59M for Drugs that Gain “Entry” to Cells | Frank Vinluan | 12/18/18 | Boston |
| Harvard Spinout 28-7 Launches with $65M for MicroRNA Cancer Drugs | Frank Vinluan | 09/06/18 | Boston |
| Cullinan Oncology Emerges with $150M to Build Cancer Drug Portfolio | Frank Vinluan | 10/03/17 | Boston |
| Not Resting on Hemophilia Biz, Bioverativ Pays $400M For True North | Ben Fidler | 05/23/17 | Boston |
| Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M | Ben Fidler | 04/13/17 | New York |
| Rhythm Raises $41M to Bankroll Late-Stage Push For Obesity Drug | David Holley | 02/16/17 | Boston |
| Takeda, Maverick Therapeutics Enter $125M Cancer Therapy Partnership | Frank Vinluan | 01/11/17 | San Francisco |
| TCR2 Therapeutics Unveils New Cancer Therapy Approach and $44.5M Round | Frank Vinluan | 12/08/16 | Boston |
| Iconic Therapeutics Lands $10,000,000 Series C Financing | VentureDeal | 08/10/16 | San Francisco |
| Oncorus Lands $57,000,000 Series A Financing Round | VentureDeal | 07/20/16 | Boston |
| Oncorus Bags $57M, Touts Next-Gen Take on Cancer-Fighting Viruses | Ben Fidler | 07/19/16 | Boston |
| Blade Therapeutics Garners $45,000,000 Series B Funding | VentureDeal | 06/20/16 | San Francisco |
| Harpoon Therapeutics Garners $15,000,000 New Financing | VentureDeal | 03/31/16 | San Francisco |
| Tizona Therapeutics Obtains $43,000,000 Series B Funding | VentureDeal | 03/08/16 | San Francisco |
